Brief: Bio-Path Granted Key Mechanism Of Action U.S. Patent For Bp1003
22/06/2021 12:20
June 22 (Reuters) - Bio Path Holdings Inc BPTH.O :
* BIO-PATH GRANTED KEY MECHANISM OF ACTION U.S. PATENT FOR
BP1003
Source text for Eikon: ID:nGNX92jm7q
Further company coverage: BPTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bio Path Holdings
See all newsBrief: Bio-Path Holdings Seeks Financing For Turnaround & Strategic Actions
Brief: Bio-Path Holdings Reports Full Year 2024 Financial Results
Brief: Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Brief: Bio-Path Provides Key Clinical Updates
Brief: Bio-Path Holdings Provides Update From Phase 1/1B Clinical Trial Of Bp1002 For Treatment Of Refractory/Relapsed Acute Myeloid Leukemia